SapC-DOPS nanovesicles as targeted therapy for lung cancer

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 491-498

  Zhao, Shuli ^a   Chu, Zhengtao ^b,c   Blanco, Victor M ^b   Nie, Yunzhong ^d   Hou, Yayi ^d   Qi, Xiaoyang ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DIOLEOYLPHOSPHATIDYLSERINE; PHOSPHATIDYLSERINE; SAPOSIN C DIOLEOYLPHOSPHATIDYLSERINE; UNCLASSIFIED DRUG; 1,2-DIOLEOYLPHOSPHATIDYLSERINE; LIPOSOME; NANOMATERIAL; SPHINGOLIPID ACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG BINDING; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LUNG CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL DEATH; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LUNG NEOPLASMS; MICE, NUDE; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; PHOSPHATIDYLSERINES; SAPOSINS; UNILAMELLAR LIPOSOMES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923373526     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0661     Document Type: Article

References (36)

1. Stewart B, Wild C. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer. World Health Organization; 2014.
2. Field RW, Withers BL. Occupational and environmental causes of lung cancer. Clin Chest Med 2012;33:681-703.
3. Fucic A, Gamulin M, Ferencic Z, Rokotov DS, Katic J, Bartonova A, et al. Lung cancer and environmental chemical exposure: a review of our current state of knowledge with reference to the role of hormones and hormone receptors as an increased risk factor for developing lung cancer in man. Toxicol Pathol 2010;38:849-55.
4. Hubaux R, Becker-Santos D, Enfield K, Lam S, Lam W, Martinez V. Arsenic, asbestos and radon: emerging players in lung tumorigenesis. Environ Health 2012;11:89.
5. Kurt Straif AC, Jonathan Samet, eds. Scientific Publication No. 161: Air Pollution and Cancer. Lyon, France: IARC Scientific Publications; 2013.
6. Ahmad I, Longenecker M, Samuel J, Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 1993;53:1484-8.
7. Sawant R, Torchilin V. Challenges in development of targeted liposomal therapeutics. AAPS J 2012;14:303-15.
8. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012;164:138-44.
9. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48.
10. Slingerland M, Guchelaar H-J, Rosing H, Scheulen ME, van Warmerdam LJ, Beijnen JH, et al. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. Clin Ther 2013;35:1946-54.
11. Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 2011;68:945-50.
12. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012;7:49.
13. Slingerland M, Guchelaar H-J, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012;17:160-6.
14. Henry B, Moller C, Dimanche-Boitrel MT, Gulbins E, Becker KA. Targeting the ceramide system in cancer. Cancer Lett 2013;332:286-94.
15. Mullen TD, Obeid LM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem 2012;12:340-63.
16. Vaccaro AM, Ciaffoni F, Tatti M, Salvioli R, Barca A, Tognozzi D, et al. pH-dependent conformational properties of saposins and their interactions with phospholipid membranes. J Biol Chem 1995;270:30576-80.
17. de Alba E, Weiler S, Tjandra N. Solution structure of human saposin C: pH-dependent interaction with phospholipid vesicles. Biochemistry 2003;42:14729-40.
18. Liu A, Qi X. Molecular dynamics simulation of saposin C-membrane binding. Open Struct Biol J 2008;2:21-30.
19. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002;54:1479-84.
20. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991;51:3062-6.
21. Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP, Cripe TP. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res 2009;15:5840-51.
22. Kaimal V, Chu Z, Mahller YY, Papahadjopoulos-Sternberg B, Cripe TP, Holland SK, et al. Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol 2011;13:886-97.
23. Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, et al. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther 2013;21:1517-25.
24. Chu Z, Abu-Baker S, Palascak MB, Ahmad SA, Franco RS, Qi X. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS ONE 2013;8:e75507.
25. Abu-Baker S CZ, Stevens AM, Li J, Qi X. Cytotoxicity and selectivity in skin cancer by SapC-DOPS nanovesicles. J Cancer Ther 2012;3:321-6.
26. Blanco VM, Chu Z, Vallabhapurapu SD, Sulaiman MK, Kendler A, Rixe O, et al. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget 2014;5:7105-18.
27. Qi X, Leonova T, Grabowski GA. Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J Biol Chem 1994;269:16746-53.
28. Mahata S, Maru S, Shukla S, Pandey A, Mugesh G, Das BC, et al. Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC Complement Altern Med 2012;12:15.
29. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 1997;88:1205-10.
30. Ramlogan-Steel CA, Steel JC, Morris JC. Lung cancer vaccines: current status and future prospects. Transl Lung Cancer Res 2013;3:46-52.
31. Morrison BJ, Steel JC, Morris JC. Immunotherapy in lung cancer: the potential of cancer stem cells in future therapies. Future Oncol 2013;9:623-5.
32. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-9.
33. Huber RM, Reck M, Thomas M. Current status and future strategies for multimodality treatment of unresectable stage III non-small-cell lung cancer. Eur Respir J 2013;42:1119-33.
34. Zhang L, Zhao D. Liposomal encapsulation enhances in vivo near infrared imaging of exposed phosphatidylserine in a mouse glioma model. Molecules 2013;18:14613-28.
35. Zhou H, Stafford JH, Hallac RR, Zhang L, Huang G, Mason RP, et al. Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging. J Biomed Nanotechnol 2014;10:846-55.
36. Ditaranto-Desimone K, Saito M, Tekirian T, Saito M, Berg M, Dubowchik G, et al. Neuronal endosomal/lysosomal membrane destabilization activates caspases and induces abnormal accumulation of the lipid secondary messenger ceramide. Brain Res Bull 2003;59:523-31.